Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c01720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Guanlu Long und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009…. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone Deacetylase Inhibitors, Leukemia, Myeloid, Acute, Histone-Lysine N-Methyltransferase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Government of Jiangsu Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Targeting the WDR5-MLL1 protein-protein interaction (PPI) is considered to be an effective approach for the treatment of MLL-rearranged leukemia. However, interfering with WDR5-MLL1 PPI reduces methylated H3K4 levels and induces a decline in acetylated H3 levels, which may contribute to the suboptimal cellular efficacy of WDR5 inhibitors. We observed that cotreatment with WDR5-MLL1 PPI and HDAC inhibitors augmented the antiproliferative effect in MV-4-11 cells. Thus, a series of dual-target inhibitors was developed by merging the pharmacophores of the WDR5 and HDAC inhibitors. Among the developed inhibitors, compound 32d displayed an 89-fold increase in antiproliferative efficacy and induced potent cell apoptosis by impeding the DNA damage repair signaling pathway. Furthermore, the administration of 30 mg/kg of compound 32d was well tolerated, inhibiting MV-4-11 xenograft growth by 87.1%. Our investigation established the therapeutic effectiveness of the developed WDR5-MLL1/HDAC dual-target inhibitor against acute myeloid leukemia, providing a valuable tool for further exploration of crosstalk between the two targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
ORCID-Profile: Zhengyu Jiang, Qidong You, Xiaoke Guo
Förderung
- Natural Science Foundation of Jiangsu Province
- Government of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Long, G., Wang, X., Chen, X., Ma, S., Sun, L., Jiang, Z., You, Q., & Guo, X. (2025). Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01720
Vancouver
Long G, Wang X, Chen X, Ma S, Sun L, Jiang Z, et al. Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01720
BibTeX
@article{Long2025,
author = {Long, Guanlu and Wang, Xianghan and Chen, Xin and Ma, Sai and Sun, Liangkui and Jiang, Zhengyu and You, Qidong and Guo, Xiaoke},
title = {Discovery of WDR5–MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c01720}
}
EUVIMED